Parkinson’s disease is a progressive neurodegenerative disorder which results in depletion of dopamine within the substantia nigra pars compacta in the central nervous system.
Featured Learning Zones
Parkinson’s disease primarily affects the motor system causing the classical symptoms of bradykinesia, tremor and rigidity. In addition, Parkinson’s disease results in non-motor symptoms such as depression and dementia which can worsen over time.
The exact cause of Parkinson’s disease is unknown and there are no disease-modifying treatments. However, dopaminergic pharmacotherapies designed to restore depleted dopamine in the brain are the mainstay of treatment. These include levodopa, dopamine agonists and monoamine oxidase B (MAO-B) inhibitors.
As Parkinson’s disease progresses, motor complications emerge related to long-term symptomatic treatment. This requires more frequent dosing or the addition of other therapies, such as catechol-O-methyltransferase (COMT) inhibitors.
Visit our dedicated Parkinson’s disease Learning Zone for learning resources on diagnosing motor fluctuations, treatment guidelines and the available COMT inhibitors.
Related news and insights
AbbVie has announced that continuous 24 hours/day subcutaneous infusion of ABBV 951 (foslevodopa/foscarbidopa) was statistically superior to oral levodopa/carbidopa in reducing motor fluctuations in patients with advanced Parkinson's disease (PD) in a Phase III, randomized, double-blind, double-dummy, active-controlled study.
Supernus Pharmaceuticals Inc, and Adamas Pharmaceuticals, Inc., announced a definitive agreement for Supernus to acquire Adamas through a tender offer for $8.10 per share in cash (or an aggregate of approximately $400 million), payable at closing plus two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash (or an aggregate of approximately $50 million), for a total consideration of $9.10 per share in cash (or an aggregate of approximately $450 million).
Amneal Pharmaceuticals, Inc. announced positive topline results from the pivotal Phase III RISE-PD clinical trial that evaluated the novel formulation, IPX 203, in patients with Parkinson’s disease (PD) who have motor fluctuations.